Nemera sustainability score: 51/100
Nemera is a privately owned French maker of drug-delivery devices such as inhalers and injectors, headquartered in Lyon. It had about 3,300 employees and about €700 million revenue in 2025.
Head office Lyon, FranceStaff ~3,300 (2025)Revenue ~€700M (2025)Website ↗
Nemera's total footprint has risen for two years, to 126,000 tCO2e in 2025, after falling from its 2019 level. It has already met its SBTi target to cut its own emissions 90%, but its value-chain target is per unit of value added. Its electricity is all carbon-free, 65% of it renewable, and its sustainability report is not independently assured.
Nemera scores 51/100 (Making progress) on SINK's independent climate assessment, scored from public data only. Scores are free. Companies can never pay for anything about their own score. Last verified October 2026.
That places Nemera joint 129th of 900 companies scored, and joint 3rd of 21 in Healthcare / Pharmaceuticals.
What is Nemera doing well, and where does it fall short?
Strongest on Carbon Footprint — Operations and Controversies & Red Flags (8/10, 8/10). Weakest on Emissions Trajectory and Nature & Biodiversity Impact (3/10, 4/10).
Where Nemera lost points
For each question that lost points, the evidence our public rubric looks for that we didn't find.
- Emissions from its own operations8/10No verified figures published with their method and a falling trend.
- Emissions from its supply chain7/10No full value-chain map or supplier engagement programme.
- Whether its emissions are falling3/10No evidence its emissions are falling, not even from energy bills or mileage.
- How clean its energy is6/10Less than 90% of its energy shown to be renewable.
- Its effect on nature4/10Its effect on nature isn't measured or independently verified.
- How it uses materials and handles waste5/10No measurable waste or recycling targets reported publicly.
- Its effect on water4/10No measured water footprint with reduction targets.
- Its climate targets7/10Its targets aren't validated by the Science Based Targets initiative.
- How openly it reports6/10No annual impact report, or no pay linked to climate targets.
A score changes when the evidence does. We use new published evidence at the next rescore. Anyone can send us new evidence, free. How to send it.
How is Nemera's SINK score calculated?
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleWhat evidence is Nemera's score based on?
11 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
45% of them were published by Nemera itself; the rest come from independent sources.
“already reached, and in fact exceeded,”
“Employant plus de 500 salariés en France, l’entreprise est soumise à”
“Nemera commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2030 from a 2019 base year.”
“Nemera 2023 2030 Biotech, health care & pharma France”
“Astorg Partners and Montagu Private Equity are evaluating options to sell their controlling interest in Nemera.”
“Astorg Partners and Montagu Private Equity are negotiating with consultants regarding the potential sale of Nemera assets”
“Since 2023, 100% of Nemera’s factories have been using green or decarbonised energy.”
“Nemera designs and manufactures a full range of drug delivery systems including asthma inhalers, insulin pens, auto-injectors and nasal pumps.”
“With this acquisition Nemera establishes an operational footprint in Brazil”
“Nemera designs, develops and manufactures complex drug delivery devices from seven manufacturing sites in France, the US, Germany, Poland and Brazil.”
“provides data and results on the actions we’ve in place”
If you believe a source has been misread or a newer version exists, submit a challenge.
Is this your company? Claim this profile (free)
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Send new evidence, free
Scored low because little is published? Publish what you do and send us the link, free. If it holds up, your score changes, and the change is logged on your page.
How to send evidence →Put your score on your website, free
It shows the current score and links to this page, so it changes when the score does.
Track this score
Bidding for a public contract? Check if you need a Carbon Reduction Plan, free →
Want your own page like this?
Free, independent, every source shown. Send it to any buyer who asks about your sustainability.
How does Nemera compare with other healthcare / pharmaceuticals companies?
Where Nemera sits among healthcare / pharmaceuticals peers.
Among the 21 major healthcare / pharmaceuticals brands we've scored, Nemera is tied =3rd of 21, with 1 other.
Who scores higher in Healthcare / Pharmaceuticals?
The 2 companies in the sector scoring nearest above Nemera.
Smith & Nephew reports genuine 63% absolute emissions cuts (Scope 1+2) and 59% Scope 3 reductions since 2021, backed by third-party verification.
See the breakdown →Novartis cut its emissions to 4.36 MtCO2e in 2025, with Scope 1 and 2 down 45% and Scope 3 down 17% against 2022, under SBTi-validated targets for net zero by 2040.
See the breakdown →Which companies moved this week, and why.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
We'll send one email to confirm. No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Scores are free. Companies can never pay for anything about their own score.